MG53通过NF-κB调控KChIP2与Ito,f参与心肌肥厚电重构
该研究在小鼠和新生大鼠心室肌细胞中操纵MG53表达,发现MG53缺失下调KChIP2与Ito,f,过表达则上调;在苯肾上腺素诱导的细胞肥厚和主动脉缩窄诱导的小鼠肥厚中,MG53降低伴随KChIP2与Ito,f下调,MG53敲除加重Ito,f重构、动作电位延长及室性心律失常易感性。机制上MG53通过调控NF-κB活性及与TAK1、IκBα相互作用控制KChIP2转录。
要点
- MG53缺失下调心肌KChIP2表达与Ito,f密度,过表达则上调。
- 肥厚时MG53降低伴KChIP2/Ito,f下调,MG53敲除加重电重构和心律失常易感。
- MG53经NF-κB调控KChIP2转录,并与TAK1、IκBα存在物理相互作用。
核心结论
- MG53是KChIP2和Ito,f的新型调控因子,通过调节NF-κB活性在心肌肥厚电生理重构中起关键作用。
研究设计与样本
- 研究采用MG53基因敲除小鼠、腺病毒过表达或RNA干扰敲低MG53的培养新生大鼠心室肌细胞,以及苯肾上腺素诱导的细胞肥厚和横向主动脉缩窄诱导的小鼠心肌肥厚模型。
主要发现
- MG53敲除小鼠心脏和MG53敲低的新生大鼠心室肌细胞中KChIP2表达与Ito,f密度下调,而MG53过表达细胞中上调。
- 苯肾上腺素诱导的心肌细胞肥厚中MG53表达降低,伴KChIP2和Ito,f下调,MG53过表达可逆转而敲低则加重。
- MG53敲除增强小鼠心肌肥厚中Ito,f重构和动作电位时程延长,并增加室性心律失常易感性。
- 机制上MG53调控NF-κB活性进而控制KChIP2转录,染色质免疫沉淀显示NF-κB蛋白与KChIP2基因相互作用。
- MG53过表达减少而敲低增加NF-κB在KChIP2基因5'调控区的富集,正常化NF-κB活性可逆转KChIP2改变。
临床怎么用
- MG53可能作为心肌肥厚中KChIP2/Ito,f下调及心律失常易感性的潜在干预靶点,但尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: KChIP2 (K+ channel interacting protein) is the auxiliary subunit of the fast transient outward K+ current ( Ito,f) in the heart, and insufficient KChIP2 expression induces Ito,f downregulation and arrhythmogenesis in cardiac hypertrophy. Studies have shown muscle-specific mitsugumin 53 (MG53) has promiscuity of function in the context of normal and diseased heart. This study investigates the possible roles of cardiac MG53 in regulation of KChIP2 expression and Ito,f, and the arrhythmogenic potential in hypertrophy. METHODS: MG53 expression is manipulated by genetic ablation of MG53 in mice and adenoviral overexpression or knockdown of MG53 by RNA interference in cultured neonatal rat ventricular myocytes. Cardiomyocyte hypertrophy is produced by phenylephrine stimulation in neonatal rat ventricular myocytes, and pressure overload-induced mouse cardiac hypertrophy is produced by transverse aortic constriction. RESULTS: KChIP2 expression and Ito,f density are downregulated in hearts from MG53-knockout mice and MG53-knockdown neonatal rat ventricular myocytes, but upregulated in MG53-overexpressing cells. In phenylephrine-induced cardiomyocyte hypertrophy, MG53 expression is reduced with concomitant downregulation of KChIP2 and Ito,f, which can be reversed by MG53 overexpression, but exaggerated by MG53 knockdown. MG53 knockout enhances Ito,f remodeling and action potential duration prolongation and increases susceptibility to ventricular arrhythmia in mouse cardiac hypertrophy. Mechanistically, MG53 regulates NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity and subsequently controls KChIP2 transcription. Chromatin immunoprecipitation demonstrates NF-κB protein has interaction with KChIP2 gene. MG53 overexpression decreases, whereas MG53 knockdown increases NF-κB enrichment at the 5' regulatory region of KChIP2 gene. Normalizing NF-κB activity reverses the alterations in KChIP2 in MG53-overexpressing or knockdown cells. Coimmunoprecipitation and Western blotting assays demonstrate MG53 has physical interaction with TAK1 (transforming growth factor-b [TGFb]-activated kinase 1) and IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), critical components of the NF-κB pathway. CONCLUSIONS: These findings establish MG53 as a novel regulator of KChIP2 and Ito,f by modulating NF-κB activity and reveal its critical role in electrophysiological remodeling in cardiac hypertrophy.
引用
- Liu W, Wang G, Zhang C, et al. MG53, A Novel Regulator of KChIP2 and Ito,f, Plays a Critical Role in Electrophysiological Remodeling in Cardiac Hypertrophy. Circulation. 2019. PMID: 30760025. doi:10.1161/CIRCULATIONAHA.118.029413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。